Literature DB >> 22449978

miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells.

Hong-Wei Kang1, Fang Wang, Qian Wei, Yi-Fan Zhao, Min Liu, Xin Li, Hua Tang.   

Abstract

miR-20a is an important member of the miR-17-92 cluster, and its real function in cervical cancer cells is unknown. Our study demonstrated that miR-20a was upregulated in cervical cancer tissues. Overexpression of miR-20a in cervical cancer-derived cell lines, HeLa and C-33A, enhanced long-term cellular proliferation, migration and invasion, whereas inhibition of miR-20a suppressed those functions. We also confirmed that oncogenic TNKS2 is directly upregulated by miR-20a. Furthermore, suppression of TNKS2 expression could inhibit colony formation, migration and invasion of cervical cancer cells. Therefore, we concluded that miR-20a can promote migration and invasion of cervical cancer cells through the upregulation of TNKS2. Copyright Â
© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449978     DOI: 10.1016/j.febslet.2012.02.020

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  54 in total

1.  Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.

Authors:  C Gu; Q Li; Y Zhu; Y Qu; G Zhang; M Wang; Y Yang; J Wang; L Jin; Q Wei; D Ye
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-08-04       Impact factor: 5.554

2.  Association of Leukocyte Telomere Length and Genes Involved in its Regulation With Oral Carcinoma.

Authors:  Zaneta Jumatovaite; Albertas Kriauciunas; Alvita Vilkeviciute; Greta Gedvilaite; Vykintas Liutkevicius; Virgilijus Uloza; Alina Smalinskiene; Rasa Liutkeviciene
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  microRNA-218 expression and its association with the clinicopathological characteristics of patients with cervical cancer.

Authors:  Bei-Bei Tang; Shui-Yi Liu; Y U Zhan; Li-Qing Wei; Xiao-Lu Mao; Jin Wang; L I Li; Zhong-Xin Lu
Journal:  Exp Ther Med       Date:  2015-04-28       Impact factor: 2.447

4.  MicroRNA expression profiling of human blood monocyte subsets highlights functional differences.

Authors:  Truong-Minh Dang; Wing-Cheong Wong; Siew-Min Ong; Peng Li; Josephine Lum; Jinmiao Chen; Michael Poidinger; Francesca Zolezzi; Siew-Cheng Wong
Journal:  Immunology       Date:  2015-07       Impact factor: 7.397

5.  MiR-15a-16 represses Cripto and inhibits NSCLC cell progression.

Authors:  Feng Chen; Shi-ke Hou; Hao-jun Fan; Ying-fu Liu
Journal:  Mol Cell Biochem       Date:  2014-02-06       Impact factor: 3.396

Review 6.  Epigenetics and cervical cancer: from pathogenesis to therapy.

Authors:  Jinchuan Fang; Hai Zhang; Sufang Jin
Journal:  Tumour Biol       Date:  2014-02-20

7.  Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment.

Authors:  Daniel J Coleman; Sharmeen Chagani; Stephen Hyter; Anna M Sherman; Christiane V Löhr; Xiaobo Liang; Gitali Ganguli-Indra; Arup K Indra
Journal:  Mol Cancer Res       Date:  2014-09-04       Impact factor: 5.852

8.  HPV 16 E7 inhibits OSCC cell proliferation, invasion, and metastasis by upregulating the expression of miR-20a.

Authors:  Jun Hu; Weili Ge; Junfeng Xu
Journal:  Tumour Biol       Date:  2016-01-19

9.  miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3).

Authors:  Ling-yun Zhang; Min Liu; Xin Li; Hua Tang
Journal:  J Biol Chem       Date:  2012-12-04       Impact factor: 5.157

10.  HPV E6/p53 mediated down-regulation of miR-34a inhibits Warburg effect through targeting LDHA in cervical cancer.

Authors:  Rong Zhang; Jing Su; Song-Lin Xue; Hui Yang; Li-Li Ju; Ying Ji; Kai-Hua Wu; Yan-Wei Zhang; Ye-Xin Zhang; Jian-Fang Hu; Min-Min Yu
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.